It is typical to encounter a restricted number of APIs during the initial stages of drug development. This limitation hinders the swift advancement of the development process. Renejix introduces an innovative strategy that facilitates the utilization of large-scale machinery right from the outset, potentially leading to the production of cGMP batches with favorable yields.
Similar Posts
Streamlined Clinical Supply Services: RxReach Direct-to-Patient
Direct-to-Patient Clinical Supply Services: Amid the surge in remote clinical studies, the imperative of facilitating direct-to-patient distribution of clinical supplies has gained…
Solid State Form Characterization for Drug Development
Characterizing an API’s different salt forms and polymorphs is an essential drug development task. The successful preclinical assessment and product development can…
Early Phase Development Using Integrated Solutions
A newly formed pharmaceutical company was creating a novel cardiometabolic drug, a new small molecule, that was in Phase 2a testing in…
FormaDoseâ„¢ Design: Solution For Dosage Form Selection
FormaDose® Design Solution is a comprehensive drug design assessment consisting of a holistic review of the molecule, patient, and market considerations. Led…
Commonly Asked Questions about Elemental Impurities
If scientific literature indicates that elements are not likely to be present in drug product components, and no additional elements are added…